The Overweight and Obesity Landscape in France: Data from the French Cohort of the Multi-country IMPACT-O Study

INTRODUCTION: The epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT-O) study was a multi-country, retrospective cohort study that utilised healthcare databases to determine the landscape/impact of overweight and obesity. Here we describe the sociodemographic, clinical and treatment characteristics of adults with a first record of overweight/obesity or obesity in France. METHODS: (obesity cohort) and a ≥ 12-month observation period before and after their first record indicating overweight/obesity or obesity. Demographic and clinical parameters, including obesity-related complications (ORCs), as recorded by physicians contributing to the database, were described. RESULTS: Of 10,206,481 subjects in the France LPD, 93,714 were included in the overweight/obesity and 46,252 in the obesity cohort; of these, 58.9% and 63.1%, respectively, had ORCs. Hypertension was the most frequently recorded ORC for both cohorts (28.8% and 32.9%, respectively). The proportion of people receiving pharmacological therapies with an effect on weight was ≤ 3%; no lifestyle interventions or bariatric surgery were recorded. CONCLUSION: These results highlight the high burden of ORCs in adults with overweight or obesity at first available record and the limited use of pharmacological treatment with an effect on weight. Improving weight-related data capture in centralised electronic medical records could facilitate the integration of multidisciplinary approaches and better support the management of obesity. Graphical Abstract available for this article.

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-04-22
DOI
https://doi.org/10.1007/s12325-026-03589-1
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Overweight and Obesity Landscape in France: Data from the French Cohort of the Multi-country IMPACT-O Study

Esther Artime, David Jacobi, Atif Adam, Aya Kayali et al.
Advances in Therapy
Pharmacology and Obesity Treatment
article

The Overweight and Obesity Landscape in France: Data from the French Cohort of the Multi-country IMPACT-O Study

Esther Artime, David Jacobi, Atif Adam, Aya Kayali, Anastasia Lampropoulou, Marine Bertrand
article en

Abstract

INTRODUCTION: The epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT-O) study was a multi-country, retrospective cohort study that utilised healthcare databases to determine the landscape/impact of overweight and obesity. Here we describe the sociodemographic, clinical and treatment characteristics of adults with a first record of overweight/obesity or obesity in France. METHODS: (obesity cohort) and a ≥ 12-month observation period before and after their first record indicating overweight/obesity or obesity. Demographic and clinical parameters, including obesity-related complications (ORCs), as recorded by physicians contributing to the database, were described. RESULTS: Of 10,206,481 subjects in the France LPD, 93,714 were included in the overweight/obesity and 46,252 in the obesity cohort; of these, 58.9% and 63.1%, respectively, had ORCs. Hypertension was the most frequently recorded ORC for both cohorts (28.8% and 32.9%, respectively). The proportion of people receiving pharmacological therapies with an effect on weight was ≤ 3%; no lifestyle interventions or bariatric surgery were recorded. CONCLUSION: These results highlight the high burden of ORCs in adults with overweight or obesity at first available record and the limited use of pharmacological treatment with an effect on weight. Improving weight-related data capture in centralised electronic medical records could facilitate the integration of multidisciplinary approaches and better support the management of obesity. Graphical Abstract available for this article.

Advances in Therapy
Centre National de la Recherche Scientifique (FR), Inserm (FR), Eli Lilly (United States) (US), IQVIA (United Kingdom) (GB), Institut du Thorax (FR)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 10%
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.